The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C

References

• Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29:7207–6. doi:10.1016/j.vaccine.2011.06.056.
   PubMed Web of Science ®Google Scholar
• Grant LR, O’Brien SE, Burbidge P, Haston M, Zancolli M, Cowell L, Johnson M, Weatherholtz RC, Reid R, Santosham M, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One. 2013;8:e74906. doi:10.1371/journal.pone.0074906.
   PubMed Web of Science ®Google Scholar
• The Pink Book: epidemiology and prevention of vaccine-preventable diseases. 14th ed. Chapter 17: pneumococcal disease [Internet]. Centers for Disease Control and Prevention; 2021 [accessed 2023 June 12]. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.
   Google Scholar
• Pneumococcal disease [Internet]. World Health Organization; 2021 [accessed 2021 Nov 29]. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease.
   Google Scholar
• Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage among children, U.S. [Internet]. Gierke R; 2022 [accessed 2022 Sept 8]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-23-24/02-pneumococcal-gierke-508.pdf.
   Google Scholar
• Pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein) Prevnar® [Internet]. Pfizer; 2009 [accessed 2021 Aug 16]. http://labeling.pfizer.com/showlabeling.aspx?id=134.
   Google Scholar
• Lochen A, Croucher NJ, Anderson RM. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020;10:18977. doi:10.1038/s41598-020-75691-5.
   PubMed Web of Science ®Google Scholar
• Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B, Shelly MA, Mahon BE, Nahm MH. Active bacterial core surveillance team. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis. 2008;198:1818–22. doi:10.1086/593339.
   PubMed Web of Science ®Google Scholar
• Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45:1225–33. doi:10.1128/JCM.02199-06.
   PubMed Web of Science ®Google Scholar
• Park IH, Park S, Hollingshead SK, Nahm MH. Genetic basis for the new pneumococcal serotype, 6C. Infect Immun. 2007;75:4482–9. doi:10.1128/IAI.00510-07.
   PubMed Web of Science ®Google Scholar
• Carvalho Mda G, Pimenta FC, Gertz RE, Jr., Joshi HH, Trujillo AA, Keys LE, Findley J, Moura IS, Park IH, Hollingshead SK, et al. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol. 2009;47:554–9. doi:10.1128/JCM.01919-08.
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Bajaksouzian S, Bonomo RA, Good CE, Windau AR, Hujer AM, Massire C, Melton R, Blyn LB, Ecker DJ, et al. Occurrence, distribution, and origins of Streptococcus pneumoniae serotype 6C, a recently recognized serotype. J Clin Microbiol. 2009;47:64–72. doi:10.1128/JCM.01524-08.
   PubMed Web of Science ®Google Scholar
• Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis. 2009;199:320–5. doi:10.1086/596064.
   PubMed Web of Science ®Google Scholar
• Nunes S, Valente C, Sa-Leao R, de Lencastre H. Temporal trends and molecular epidemiology of recently described serotype 6C of Streptococcus pneumoniae. J Clin Microbiol. 2009;47:472–4. doi:10.1128/JCM.01984-08.
   PubMed Web of Science ®Google Scholar
• PREVNAR 13 (Pneumococcal 13-valent conjugate vaccine [Diphtheria CRM197 Protein]) [Internet]. Pfizer; 2017 [accessed 2022 Sept 29]. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM574852.pdf.
   Google Scholar
• Prevnar 13 summary of product characteristics [Internet]. Pfizer; 2020 [accessed 2022 Nov 16]. https://www.medicines.org.uk/emc/medicine/22689#DOCREVISION.
   Google Scholar
• Ahmed SS, Pondo T, Xing W, McGee L, Farley M, Schaffner W, Thomas A, Reingold A, Harrison LH, Lynfield R, et al. Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions-United States. Clin Infect Dis. 2020;70:2484–92. doi:10.1093/cid/ciz739.
   PubMed Web of Science ®Google Scholar
• Porat N, Benisty R, Givon-Lavi N, Trefler R, Dagan R. The impact of pneumococcal conjugate vaccines on carriage of and disease caused by Streptococcus pneumoniae serotypes 6C and 6D in southern Israel. Vaccine. 2016;34:2806–12. doi:10.1016/j.vaccine.2016.04.043.
   PubMed Web of Science ®Google Scholar
• Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P. Long-term impact of a “3 + 0” schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002–2014. Clin Infect Dis. 2017;64:175–83. doi:10.1093/cid/ciw720.
   PubMed Web of Science ®Google Scholar
• Fenoll A, Ardanuy C, Linares J, Cercenado E, Marco F, Fleites A, Rodriguez-Mayo M, Lopez-Hontangas JL, Palop B, Aller AI, et al. Serotypes and genotypes of S. pneumoniae isolates from adult invasive disease in Spain: a 5-year prospective surveillance after pediatric PCV13 licensure. The ODIN study. Vaccine. 2018;36:7993–8000. doi:10.1016/j.vaccine.2018.10.098.
   PubMed Web of Science ®Google Scholar
• Narvaez PO, Gomez-Duque S, Alarcon JE, Ramirez-Valbuena PC, Serrano-Mayorga CC, Lozada-Arcinegas J, Bastidas A, Gomez S, Vargas H, Feldman C, et al. Invasive pneumococcal disease burden in hospitalized adults in Bogota, Colombia. BMC Infect Dis. 2021;21:1059. doi:10.1186/s12879-021-06769-2.
   PubMed Web of Science ®Google Scholar
• VAXNEUVANCE™ (Pneumococcal 15-valent conjugate vaccine) prescribing information [Internet]. Food And Drug Administration; 2021 [accessed 2023 Apr 4]. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance.
   Google Scholar
• Vaxneuvance summary of product characteristics [Internet]. Merck & Co. I; 2022 [accessed 2022 Nov 29]. https://www.ema.europa.eu/en/documents/product-information/vaxneuvance-epar-product-information_en.pdf.
   Google Scholar
• VAXNEUVANCE® product monograph [Internet]. Health Canada; 2022 [accessed 2022 Aug 26]. https://www.merck.ca/en/wp-content/uploads/sites/20/2022/06/VAXNEUVANCE-PM_E.pdf.
   Google Scholar
• Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19:412–25. doi:10.1007/s10156-013-0601-1.
   PubMed Web of Science ®Google Scholar
• Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol. 2009;16:376–81. doi:10.1128/CVI.00344-08.
   PubMed Web of Science ®Google Scholar
• Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Gakhar V, Sterling TM, Acosta CJ, Nolan KM, Li J, Pedley A, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15:530–9. doi:10.1080/21645515.2018.1532249.
   PubMed Web of Science ®Google Scholar
• Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, Shekar T, Li J, Hurtado K, Su SC, et al. A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020;39:763–70. doi:10.1097/INF.0000000000002765.
   PubMed Web of Science ®Google Scholar
• Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol. 2012;19:835–41. doi:10.1128/CVI.00086-12.
   PubMedGoogle Scholar
• Park S, Parameswar AR, Demchenko AV, Nahm MH. Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups. Infect Immun. 2009;77:3374–9. doi:10.1128/IAI.00319-09.
   PubMed Web of Science ®Google Scholar
• Zhou J, Lottenbach KR, Barenkamp SJ, Reason DC. Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B. Infect Immun. 2004;72:3505–14. doi:10.1128/IAI.72.6.3505-3514.2004.
   PubMed Web of Science ®Google Scholar
• Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, Mereckiene J, Knol M, Winje BA, Ciruela P, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022;40:3963–74. doi:10.1016/j.vaccine.2022.05.011.
   PubMed Web of Science ®Google Scholar